| scholarly article | Q13442814 |
| P356 | DOI | 10.1089/JOP.2009.0091 |
| P698 | PubMed publication ID | 20415623 |
| P2093 | author name string | Sanjay N Rao | |
| P433 | issue | 2 | |
| P921 | main subject | cyclosporine | Q367700 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 157-164 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Journal of Ocular Pharmacology and Therapeutics | Q15755845 |
| P1476 | title | Topical cyclosporine 0.05% for the prevention of dry eye disease progression | |
| P478 | volume | 26 |
| Q89536714 | An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease |
| Q57378877 | An overview on dry eye treatment: approaches for cyclosporin a delivery |
| Q47852975 | Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs. |
| Q39151688 | Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature |
| Q36556824 | Corneal Dendritic Cell Density Is Associated with Subbasal Nerve Plexus Features, Ocular Surface Disease Index, and Serum Vitamin D in Evaporative Dry Eye Disease |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q35570541 | Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q92367899 | Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study |
| Q35030126 | Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients |
| Q33748628 | High Frequency of Latent Conjunctival C. trachomatis, M. hominis, and U. urealyticum Infections in Young Adults with Dry Eye Disease |
| Q41350375 | Incomplete response to artificial tears is associated with features of neuropathic ocular pain. |
| Q37471561 | Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up |
| Q41862908 | Lower Vitamin D Level and Distinct Tear Cytokine Profile Were Observed in Patients with Mild Dry Eye Signs but Exaggerated Symptoms |
| Q36444344 | PERSIST: Physician's Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review |
| Q52608828 | Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. |
| Q39030112 | Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye. |
| Q91827428 | Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye |
| Q38171801 | Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. |
| Q36039088 | The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye |
| Q38270449 | The role and treatment of inflammation in dry eye disease |
| Q26822610 | Therapeutic Strategies to Treat Dry Eye in an Aging Population |
| Q90093016 | Topical cyclosporine A therapy for dry eye syndrome |
| Q35565484 | Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery |
Search more.